Viread leads outpatient prescription market last July, chased by Lipitor

Published: 2017-09-05 14:29:03

Updated: 2017-09-05 14:29:03

While Gilead Sciences’ Viread was rushing at the top in the outpatient prescription market last July, Lipitor was chasing after it. Among the top 15 medicines, in addition, Chong Kun Dang’s Gliatilin and Daewoong Bio’s Gliatamin, the two products, recorded a double-digit growth rate.

According to the HMC Investment Securities’ ‘Top 15 Outpatiently Prescribed Medicines on July 2017’ which analy...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.